CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Deferasiroxdrug
Likely dose
Deferasirox 30mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00447694
NCT00447694Phase 2Completed
CompareCT.gov

An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months

Novartis·interventional·Posted Mar 15, 2007·Updated Jun 14, 2021

In Brief

A Phase 2 clinical trial evaluating Deferasirox for Beta-thalassemia and Iron Overload. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2\* in beta-thalassemia patients with deferasirox treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBeta-thalassemia, Iron Overload
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 15, 2007
Enrollment StartFeb 1, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.3 years ago

Interventions

Deferasiroxdrug

Oral deferasirox 30mg/kg/day once per day for 77 weeks.